Hubei JXBio Pharmaceutical Co.,Ltd.

Hubei JXBio Pharmaceutical Co., Ltd. is located in the Xian’an Economic Development Zone in Hubei Province and specializes in the production of GLP-1 receptor agonist peptides and other peptide APIs. It also undertakes the manufacturing of certain CDMO peptide projects. This production base spans 300 acres, with a total building area of approximately 54,000 square meters. The facility includes four peptide production workshops, a quality control and R&D building, Class A and Class B warehouses, a solvent recovery center, a power center, a solid waste collection area, and a wastewater treatment plant.Hubei JXBio has established 10 GMP-compliant peptide API production lines (including pilot-scale production lines) that meet U.S. FDA, European EMA, and Chinese NMPA cGMP standards. The facility is equipped with dozens of solid-phase and liquid-phase peptide synthesis reactors, with a total reactor volume exceeding 30,000 liters. The company has implemented a comprehensive pharmaceutical quality management system (QMS) and an Environmental, Health, and Safety (EHS) management system. It has successfully passed GMP compliance inspections by the NMPA, multiple third-party quality audits, and EHS audits conducted by globally leading clients.With an annual peptide API production capacity reaching several metric tons, Hubei JXBio is a highly competitive manufacturer of chemically synthesized peptide APIs in both domestic and international markets. The facility leads the industry in single-batch production capacity for GLP-1 peptide products in China, while certain cosmetic peptides have single-batch yields exceeding 100 kg.

Hubei JXBio 's future development and planning

Rapidly expand the scale of the company's products, realize the industrialization of the company's research and development results, and form economies of scale. At the same time, it has formed good social benefits and promoted the attraction of foreign investment, the introduction of technology and talents, and the promotion of regional medicine and related industries in the Xian'an area.

After the project is fully put into production, the company will realize an annual sales income of 1.5 billion yuan, total tax payment of more than 200 million yuan, and solve the employment of more than 1,000 people. After 5 years of production, the company's sales revenue is expected to exceed RMB 3 billion, achieving simultaneous economic, social and environmental benefits.

In the next few years, the company will continue to strengthen domestic and international market expansion and actively occupy the domestic market for peptide products. Develop overseas strategic partners, continue to strengthen the registration and certification of products overseas, and gradually enter the market for regulating the national peptide raw materials. And continue to enhance the brand's international visibility, making overseas business an important growth point for the company's revenue and profits.